GlassScriptPhysician profile
Carmen Murillo
NPI 1982149159
$8,944.90
in general payments reported to CMS, 2019-2025
24 companies · $4,575 in 2025
The $4,575 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $529 · 2022: $616 · 2023: $1,829 · 2024: $1,396 · 2025: $4,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,904 · Travel and Lodging: $763 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,903.90 |
| Travel and Lodging | $762.85 |
| Education | $132.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,866.50 | 2021-2025 | |
| Amgen INC. | $1,673.39 | 2021-2025 | Evenity, Otezla, Krystexxa |
| Ucb Sa | $1,062.97 | 2025 | |
| Ucb, INC. | $651.93 | 2023-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $640.92 | 2022-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $602.50 | 2022-2025 | Ofev |
| Janssen Biotech, INC. | $530.79 | 2022-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $467.43 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $275.55 | 2021-2022 | |
| Pfizer INC. | $275.21 | 2023-2025 | |
| Genzyme Corporation | $172.15 | 2025 | |
| Novo Nordisk INC | $103.28 | 2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $102.08 | 2025 | |
| Radius Health, INC. | $99.54 | 2025 | Tymlos |
| Fresenius Kabi USA, LLC | $90.12 | 2025 | Tyenne |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $75.60 | 2025 | Orencia |
| Actelion Pharmaceuticals US, INC. | $54.99 | 2023 | Uptravi, Opsumit |
| Ani Pharmaceuticals, INC. | $48.85 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $46.35 | 2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $35.16 | 2025 | Strensiq |
| Tonix Medicines, INC. | $24.06 | 2025 | Tonmya |
| Genentech USA, INC. | $17.43 | 2025 | Gazyva |
| Aurinia Pharma U.S., INC. | $14.78 | 2025 | Lupkynis |
| Allergan, INC. | $13.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Murillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.